Nivolumab is another mAb directed to PD-1 approved for use in individuals with unresectable or metastatic melanoma non-responding to other treatments, as well as in patients with metastatic NSCLC, or after platinum-based chemotherapy. Here, PDCD1 is linked to metastatic melanoma.